COMPOSITIONS, METHODS AND KITS FOR REDUCING LIPID LEVELS
1 Assignment
0 Petitions
Accused Products
Abstract
Compositions, methods, and kits useful for treating hyperlipidemic conditions are provided herein. Such compositions can contain synergizing amounts of nicotinic acid, nicotinamide riboside and/or nicotinic acid metabolites in combination with leucine and/or a leucine metabolite, with or without resveratrol.
12 Citations
135 Claims
-
1-103. -103. (canceled)
-
104. A method of lowering total cholesterol level or total lipid content in a subject in need thereof, the method comprising administering to the subject a dose of a composition comprising:
-
a) at least 250 mg of leucine and/or at least 25 mg of one or more leucine metabolites, wherein the leucine metabolite is selected from the group consisting of keto-isocaproic acid (KIC), alpha-hydroxy-isocaproic acid, and hydroxymethylbutyrate (HMB); and b) at least 1 mg of nicotinic acid and/or nicotinamide riboside and/or one or more nicotinic acid metabolites, wherein the nicotinic acid metabolite is selected from the group consisting of nicotinyl CoA, nicotinuric acid, nicotinate mononucleotide, nicotinate adenine dinucleotide, and nicotinamide adenine dinucleotide. - View Dependent Claims (105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116)
-
- 117. A method of reducing atherosclerotic plaque size in a subject in need thereof, comprising administering to said subject a dose of a composition comprising leucine and/or one or more leucine metabolites and an amount of nicotinic acid and/or nicotinic acid metabolites to effect the total atherosclerotic plaque size in the subject.
- 126. A method of reducing a side effect of nicotinic acid and/or nicotinamide riboside and/or one or more nicotinic acid metabolites wherein the side effect is characterized by an increase in cutaneous vasodilation in a subject administered with nicotinic acid and/or nicotinamide riboside and/or the one or more nicotinic acid metabolites, comprising administering a composition comprising an effective amount of leucine and/or one or more leucine metabolites to said subject that is administered with nicotinic acid and/or the one or more nicotinic acid metabolites.
Specification